SecBot SecBot
DEFA14A ·Filed Jun 1, 2026

CABA

Cabaletta Bio, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed5mo ago SEC0001193125-26-249726
Proxy solicitation materials
Actionable Insight • Neutral

The withdrawal is a procedural change with no immediate financial impact. Monitor for any future proxy filing regarding a revised equity plan proposal. The annual meeting proceeds as scheduled with the remaining proposals.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.67
T+0 close · Jun 1, 2026 · via day close
Latest settled
−12.26%
T+60 · $3.22
Vs SPY
−13.49%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 1 $3.67entry
  2. T+1 · 6mo ago +0.27%α +0.13% · $3.68
  3. T+5 · 5mo ago −11.44%α −8.69% · $3.25
  4. T+20 · 5mo ago −15.26%α −13.96% · $3.11
  5. T+60 · 3mo ago −12.26%α −13.49% · $3.22

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cabaletta Bio's board withdrew Proposal 3 (amendment to the 2019 Stock Option and Incentive Plan) from the June 9, 2026 annual meeting agenda, citing further review. The remaining five proposals (director elections, ratification of auditor, say-on-pay, etc.) will proceed as scheduled. Existing proxy cards remain valid; no new voting instructions are needed.

Key Financial Metrics

Meeting
2026-06-09

Key Facts

  • Proposal 3 (amendment to 2019 Stock Option and Incentive Plan) withdrawn from the 2026 annual meeting agenda.
  • Board determined on May 31, 2026, not to seek stockholder approval of Proposal 3.
  • All other proposals (1, 2, 4, 5, 6) remain on the agenda for the June 9, 2026 meeting.
  • Record date remains April 20, 2026; existing proxy cards remain valid without resubmission.
  • Company reserves right to propose future amendments to the equity compensation plan.

Financial Impact

No direct financial impact; removal of equity plan vote removes potential dilution from future option grants, but no dollar amounts disclosed.

dilution

Risk Factors

  • Potential future dilution if a revised equity plan is proposed later.
  • No material risk from this filing alone.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-249726
Document: 0001193125-26-249726-index-headers.html0001193125-26-249726
Document: 0001193125-26-249726-index.html0001193125-26-249726
Document: 0001193125-26-249726.txt0001193125-26-249726

Track record

29 reports on CABA

Performance horizon

4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +31.59% at T+60 after the May 4, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $1.15 Now $1.11 −3.09% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.32 Now $1.11 −15.91% settles Nov 23
  3. Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $1.33 Now $1.11 −16.54% settles Nov 19
  4. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $1.45 Now $1.11 −23.45% settles Nov 17
  5. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
  6. Nov 8, 20268d ago Press Release Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
  7. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
  8. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
  9. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $1.28 to $1.33 Now $1.11 −13.28% ▲ +3.91% +0.62% vs SPY
  10. Nov 5, 202611d ago Press Release Neutral 4/10 No price data
Showing 10 of 29

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 1, 2026